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lnterleukin-1 receptor antagonist (IL-1ra), a naturally 
occurring inhibitor of interleukin-1 (IL-1), blocks 
IL-1 binding to its receptors but has no agonistic 
activity. IL-1 is thought to play an important role in 
contact hypersensitivity (CHS), although the effects 
of exogenously administered IL-l in CHS have been 
somewhat controversial. To clarify the role ofiL-1 in 
CHS, we studied the effect ofiL-1 receptor blockade 
using exogenous IL-lra and evaluated these effects 
on CHS. We examined the in vivo effects of local 
administration of recombinant human IL-lra in the 
murine CHS model. Local injection of IL-lra to 
sensitized BALB/c mice just before challenge with 
dinitrofluorobenzene resulted in a significant reduc-
tion in the intensity ofCHS responses, assessed by ear 
swelling. A dose-response study revealed that maxi-
mal inhibition of ear swelling (36% to 43%) was 
observed after intradermal injection of IL-1ra at 
I nterleulcin-1 receptor antagonist (tL-lra) is a specific inhib-itor of interleulcin-1 (IL-l) (both IL-10' and IL-1/3) bioac-tivities. IL-lra was initially characterized by separate groups of investigators as a product of monocytes stimulated by immune complexes in 11itro [1 ], and as a component of urine 
from patients with monocytic leukemia and oth er febrile diseases 
[2,3]. IL-lra eDNA has been cloned recently from a human 
monocyte library [4]. IL-lra is now known to be a major product 
released by tissue macrophages, particularly in disease states show-
ing an acute inflammatory response [5,6]. Polymorphonuclear 
leukocytes, when stimulated, can also synthesize and secrete IL-1ra 
in culture [7] . Recently, an exclusively intracellular variant of 
IL-lra has been characterized, which is constitutively expressed on 
epithelial cells, including keratinocytes [8,9]. IL-1ra was initially 
named for its ability to block specifically and competitively the 
binding ofiL-1 species to their receptors but possesses no agonistic 
activity [5,10]. IL-1ra is considered a member of the IL-1 gene 
family because of its 19% and 25% amino acid sequence homology 
with IL-10' and IL-1J3, respectively, and has similarities in overall 
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doses of 10 to 100 p..g/ear. This reduction in ear 
swelling in IL-lra-injected ears consisted of less in-
flammatory cell infiltration and decreased edema in 
the dermis compared with controls. Suppression of 
CHS was observed when IL-lra was applied in the 
24-h interval preceding challenge with dinitrofluoro-
benzene, whereas no suppressive effect was observed 
when IL-1ra was applied 48 h before or after the 
challenge. Local administration of IL-lra to naive 
mice 5 h before sensitization also suppressed CHS 
responses. However, IL-lra injection did not suppress 
phenol-induced inflammation. These results suggest 
that IL-lra is an effective inhibitor ofboth the sensi-
tization and elicitation phases of CHS expression in 
mice, thus emphasizing the role of IL-1 as an immu-
nologic potentiator of responses associated with 
CHS. Key words: cytokiuelallevgic contact deJI"fllatitislsup-
pression. J Invest Dermatol 105:334-338, 1995 
gene structure to IL-1 [11,12]. IL-lra was initially reported co bind 
with high affinity to the 80-kD type I receptor (IL-1 tiR) expressed 
on T cells, end) thelial cell s, keratinocytes, hepatocytes, and fibro-
blasts [4,11,13]. Subsequent studies have shown that it can also 
recognize the 68-kD type II receptor (IL-ltUR) present on ueu-
trophils, B cells, and bone-marrow-derived cells [14,15]. By 
occupying receptors, IL-1ra blocks the binding of IL-1 to its 
receptors without initiating a signal in the normally responsive 
target cells. 
Contact hypersensitivity (CHS), a particular type of delayed-type 
hypersensitivity, is a T-cell-mediated immune reaction occurring 
after epicutaneous immunization and challenge with reactive hap-
tens [16]. Crucial to the development of CHS reactions are 
Langerhans cells, dendritic cells that function as the principal 
antigen-presenting cells within the epidermis, which are capable of 
both initiating and eliciting CD4-dependent immune reactions in 
the skin [17-19]. 
IL-l is believed to have important effects on numerous host 
responses to exogenous stimuli such as trauma, stress, and infection 
[20] . IL-l possesses significant proinflammatory effects and can 
elicit swelling and neutrophil accumulation at the injected site [21] . 
lt has been shown to possess some costimulative function in antigen 
presentation [22 ,23]. IL-l can up-regulate syngeneic and allogeneic 
mixed lymphocyte reaction responses of dendritic ceiJs and also has 
a mitogenic effect on dendritic cells [24,25]. IL-l-pulsed human 
dendriti c ceiJs were two- to threefold more active in terms of 
accessory cell function compared with controls [26]. Thus, IL-1 is 
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also thought to play an important role in CHS; h owever, confl icting 
effects of exogenously admi11jstered IL-1 in CHS have bee n re-
ported [27,28]. 
Recombinant IL-1 ra has been used to clarify the role of LL-1 in 
the onset and development of several p athologic conditions ;, 11i1'0 
and to address the role ofiL-1 i11 11itro [5,10,29,30]. To elucidate the 
role of IL-l in CI-:IS, we irutiated studies to block fL-1 effects u sing 
exogenous IL-1ra and to evaluate these effects o n the expression of 
CHS in mice . Our results indicate that IL-1 ra can markedly 
down-regulate the development of the CHS reaction , strongly 
supporting a c ritical role of IL-l in CHS expression. 
MATERIALS AND METHODS 
Anirrtals Female BALB/c mice were obtained from the C harles River 
Breeding Laboratory (Quebec, Canada) and used at 8-10 weeks of age. At 
least four mice were used in each experimenta l group . Each experiment was 
repeated at least three times. 
Chemicals R .. ecombinant human IL-lra (rhulL-1 ra) was supp lied by 
Upjohn Co. (Kalamazoo. Ml). The ability of this rhulL-1 ra to inhibit the 
murine fL-1-mcdiated biologic activity was demonstrated by several studies 
[31.,32]. Dinirrofluorobcnzene (DNFB) and phenol were obtained from 
Sigma Chemical Co. (St. Louis, MO) and Gibco DRL (13urlington. Ontario, 
Canada). respectively. 
Assay for CHS CHS was induced by the method described previously 
with minor modifications [33 ]. Driefly, the abdominal skin of mice was 
sbaved and painted with 20 ILl ofO.S% DNFB in 4:1 acctone:olive oil. Five 
days later, the mice were challenged on the dorsal surface of the cars with 
10 J.Ll of0.2% DNFB. Unsensitized mice were also challenged and used as 
controls for the irrita tion effects of0.2'Yo DNFD. T he extent of ear swelling 
\Vas used as a n1casure of CHS . Ear rhjckncss was n1casurcd \vith a Peacock 
spring-loaded micrometer (Ozaki Co ., Tokyo, Japan) immediately before 
chall.e nge and at 24 , 48. and 72 h after challenge. T he percent suppress ion 
was calculated acco rding to the formula: 
( 
net car swelling in IL-1 ra-i1 tiected ear ) 
Percent suppression = 1 - . . . . . X "I 00. 
net car swcllmg 111 PBS-uuccted control car 
in vvhich PBS = phosphate-buffered sahne. 
The statistical significance of the differences in mean ca r thickness 
bervvcen !L-"J ra-treated cars and contro l cars was determined by Student t 
test. We considered p < 0.05 (two-tailed test) to be signifi cant. 
Induction of lnflantmation by Phenol Fnr induction of irritant der-
matitis, 10 f.LI of 20% (vollvol) phenol in abso lute ethanol was painted on 
the mouse car. Ear thickness \Va s n1 casu red w-ith a spring-loaded 111jcron1ctcr 
at 3, 6, 1.2, and 24 h after painting. 
IL-lra Treatment To examine the efFect of local administration of 
!L-lra on the elicitation phase ofCHS, we injected IL-lra (0.1-100 ILg in 
40 J.Ll of PBS) intradermall y into one side of each e,n· immediately before 
challenge. T he mice were anesthetized with pentobt~rbital (50 mg/kg 
intraperitonea lly) (Nembutal; Abbott Laboratories. O ntario , Canada). An 
eqnaJ vo lume of PBS was injected into the e;us of the control group 
(previous studies demonstrated that there was no statistical difference 
bervveen PBS-treated animals and animals treated with an irrelevant rat IgG) 
[33]. For rin1e-course expcrin1ents. I L-1 ra was injected at various tin1es 
either before (1-48 h) or after (l-6 h) challenge . To determine whether 
intradennal injected IL-1 ra induces systemic changes. we treated one group 
of mice w ith IL-lra on the left ear and with PBS on the contralateral right 
ear before challenge, and the ear swelling was compa red at 24 and 48 h after 
the treatment. To examine the effect of !L-1 ra 0 11 the sensitization phase of 
CHS, we injected IL-1ra (10 ILg/ear) 5 h before sensitization into the right 
ear of each mouse, fo llowed by 10 ILl of 0.5% DNFB epicutaneously. Five 
days later, the mice were challenged on the left side with 10 ILl of 0.2'X• 
DNFB. lL-lra (1 0 ILg/ear) was also injec ted 2 h before phenol painting to 
examine its effect 0 11 irritant con tact dcrrna ti ti s. 
Histologic Examination Ear samples taken at 48 h after challenge were 
fixed in 10% forma lin for routine histologic staining usin g hematoxylin and 
eosin. 
RESULTS 
IL-lra Suppresses the Elicitation Phase of CHS To study 
the effect of IL-1ra on the d evelopm e nt of CHS reactions, varying 
amounts of lL-lra (0.1-100 J.Lg) in 40 ~-tl PBS were injected 
intrad ermally into the ears of sensitized mice just b efore challenge. 
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Figure 1. IL-lra suppresses CHS. (n) Suppressive effects of IL-1 ra on 
C HS arc dose dependent. Mice were sens itized and challenged with DNFB 
as described i11 /Hnte•inls n11d !VIetlwds. Immediately before cha llenge, JL-1 ra 
at doses of0.1-100 ILg in 40 ILl of PBS was injected intrade rmally imo the 
cars. An equa l vo lume of P.l3S was injected into cars of the control group 
(positive control) ;md the unsensitizcd group (negative control). T he ca r 
swelling measured at 24 h afi:er challenge was 16.5 X 1 o- 2 ::!:: 1 .4 mm in 
positive contTol llli cc and 1.9 X I o- 2 ±: ] .1 111111 in negative control Ill icc . 
Four mi e were used in each !,'TOup. The degree of suppression was 
signifi cant (two-tailed t test) in the groups receiving ·1 0-100 ILg of JL-1 ra : 
*p < 0.01 versus positive contro l. Enor bars, SEM : n = 4. (b) Time course 
for suppressive effect ofiL-lra on C I-I S. Mice it~jcctcd with either IL- l ra ( I 0 
ILg) or PBS were sensitized and challenged wirh DNFB as described in 
i\llaterinls mul Methods. Ear thickness was n1casurcd at various tin1es up to 72 
h after challenge. Significant suppression of car swelling was observed in 
IL-lra-injccted mice : *p < 0.05; **p < 0.01 versus PBS-treated mice. 
Cirrlcs, PBS-treated mice; flin11gles, IL-1 ra-treatcd mice. Enor bars, SEM; n = 
4. 
Because our previous studies demonstrated tha t th e re was n o 
statistical difterence between PBS-treated mice and mice treate d 
w ith an irre levant rat TgG in terms of the e fi-ects on ea r swelling 
[33] , control mice were treated w .ith an equal volume of PBS . Mice 
treated with IL-1 ra exhibi ted signifi ca ntl y suppressed CHS re-
spon ses to DNFB in comparison w ith PBS-injected control mice 
(Fig 1a). When IL-lra was administered a t the dose ranges 
between 10 and 100 J.Lglcar, signi ficant suppression of CHS (36% 
to 43%, p < 0 .01) was observed at all time points up to 72 h after 
the c h a ll e n ge. Figure tb shows the kinetics of car swelling when 
10 ~-tg IL-1ra was inj ected. 
At 48 h after challe n ge, car samples from sensitized and chal-
le n ged mice treated with PBS showed a marked inflammato ry 
infiltrate of polymorphonuclear lymphocytes, pronounced edema 
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Figure 2. IL-lra reduces inflammatory infiltration in the CHS 
response. H ematoxylin and eosin-sta ined sections o f ears 48 h after DNFB 
challenge of a sensitized mouse given 40 J.LI PUS (a) o r 10 J.Lg I L-1 ra (b) 
before challenge. a) Marked inAammat01·y infiltTation , pronounced edema , 
and vasod il ation arc observed in the dermis; cxocytosis, spongiosis, and 
in tracellular edema arc observed in the epidermis. b) Decreased edema and 
inAammatory infiltration in the dermis and epidermis. Figures show cross-
sections of the corresponding central areas of the ca rs. Bar, 25 J.LnL 
a.nd vasodilation in the d e rmis, and exocytosis and spongiosis in th e 
e pide rmis (Fig 2a) . Inj ection of 10 J.Lg IL-lra before c h aJJe nge le d 
to a significa nt redu ctio n in all these c hanges (Fig Z/1) . 
To d etermin e wheth er th is anti-inflammatory e ffect was from 
loca l or systemic intrade rmal IL- lra, we injected lL- 1 ra (10 J.Lg ) in 
th e left ear of each m o u se a nd treated th e contra lateral right car 
with PBS before challe nge with DNFB. Ea r swellin g was sig nifi-
cantly suppressed in those cars if1icc te d w it h IL-1 ra compared with 
th e contra.latera l control ears th at were injected with PBS (Fig 3). 
At 48 h after ch allenge, swelling in the ea rs injected w ith l L-1 ra was 
7 .3 X 10 - 2 ± 1.3 mm , whereas swellin g in the con tra la teral control 
e ars was 13 .5 X 10- 2 ± 1.5 mm. These results impl y th at loca l 
Group Treatment 
A left side: IL-1 ra 
right side: PBS 
B lL-1 ra 
c PBS 
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Net Ear Swelling (x1 o·2 mm) 
F igure 3. Local injection of IL-lra inhibi ts t he elicitation phase of 
CMS. Mice were sensitized and challenged with DNFll as described in 
Materials 11111/ M etlwds. Group A mice were treated with rL-1 ra (1 0 J.Lg/ear) on 
the left side and with PBS on the contralatera l car immediately befo re 
challenge. Group B was treated with IL-1 ra on both sides. Group C was 
treated with PBS on both cars. Ea r thickness (mean ::': SO) was measured at 48 
h afte r the challenge. Five mice were used in each gro up. Swelling to the 
IL-1 ra-pretreatcd cars was signifi cantly reduced at 48 h afte r challenge 
compared with that of the contralate ral PBS-pre treated cars (p < 0.01) in 
group A. IL-1 ra pretreatment of both cars showed signifi cant reduction of ear 
swelling at 48 h after challenge in group B compared w ith the ear swelling 
observed in group C mice (p < 0.005). 
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Figure 4. Tilne-dependnet suppressive effect of IL-1ra on CHS. 
IL-1 ra ('I 0 p,g/car) was injected at various times before or after challenge. 
Mice were sensiti zed and challenged with DNFI3 as described in i'vla lerials 
a11d Met/rods. Ear thickness was eva luated at 24 h after challenge. Significant 
suppression of ea r swelling was observed when IL- ·1 ra was injected in the 
24-h in te rva l preceding chall enge with DN FB. **p < (l.01 at 0 to - 12 h; 
*p < 0.05 at - 24 h. Error /mrs, SEM; n = 4. 
admin istration of IL-1 ra did not have any syste mic effects on the 
e lic itation phase of C HS. 
Suppressive Effect of IL-lra on CHS Is Time Dependent 
To d e termin e the optima l time for modulating CHS, w e performed 
a tim e- course study . Significant suppression (34'Y,, to 54%, p < 0.01) 
of CHS respon ses was observe d when IL-1 ra (1 0 J.Lg) was inj ecte d 
0-12 h be fo re painting with DNFll (Fig 4). T h e suppressive e ffect 
was not as promine n t (21. 7 ± 13.4%, p < 0 .05) when IL-lra was 
applie d 24 h before ch alle nge . Injection of IL-1 ra 48 h before 
DNFB treatm ent resu lte d in n o suppression of the CHS response. 
In addition, if IL-1 ra was administered 1 h o r m ore a fte r DNFB 
painting, n o su~press ion of CHS responses was seen . 
IL-lra Suppresses the Sensitization Phase of CHS In the 
pre limin ar y experiments, we confirmed that mi ce could b e sensi-
tized by painting an e ar with 10 J.Ll 0.5°/c, DNFB and e lic ite d by 
applying 10 J.Ll 0.2% DNFB to the con tralatera l ear. To dete rmine 
w heth er in tradermaliL-lra can also suppress the sen sitization ph ase 
Treatment Sensitization Challenge 
PBS DNFB DNFB 
IL·1ra DNFB DNFB 
PBS vehicle DNFB 
0 5 10 15 
Ear swelling (x10"2 mm) 
Figure 5. Local injection of IL-lra inhibits d1e sensitization phase 
of CHS. IL-1 ra (10 J.Lg/ea r) was injected intradermally in to the ear 5 h 
before sensitization with I 0 J.L I of 0.5'Y,, DNFll. Five days later. che 
contra latera l car was challenged with 0.2% DNFJ3. Ear thickness was 
measured at 48 h after the chall enge. Six mice were used in each group. 
Sign ifican t suppression of car swelling was observed in IL-1ra-pretreated 
mice: *p < 0.005 versus PBS- pretreated mi ce. Error bnrs, SEM; n = 3 . 
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Table I. IL-lra Does Not Suppress Phenol-Induced Inflammation" 
Time After Phenol Painting 
Group Treatment Before Phenol Painting 3 h 6h 12 h 24 h 
A Left ear: IL-1ra 21.8 ± 1.7 18.3 ± 1.4 7.3 ::':: 1.4 4.5 ± 0.6 
Right ear: PBS 22.3 ± 3.8 21.5 ::':: 3.5 10.0 ::':: 3.0 7.0 ::':: 2.5 
B Both ears: IL-1 ra 23 .8 ± 1.6 20.0 ± 1.8 11.1 ::':: 2.0 7.5 ::':: 1.4 
c Both ears: PBS 23.6 ± 1.3 20.0 ± 2.0 10.3 ± 1.5 5.8 ::':: 0.5 
• Mice were treated with 20% phenol as described in Materials tmd Methods. Group A mice were treated with lL-1 ra (10 p.g/car) on the left ear and with PBS on the righ t ear 
2 h before phenol painting. Group B was treated with lL- 1 ra on both cars. Group C was treated with PBS on both ears . Ear thickness (mean ::!:: SO) was measured at various tin1es 
up to 24 h. Six rnice were used in each group. 
of CHS, we injected IL-lra at the site of sensitization . IL-1 ra (10 
p.g) was injected intradennally into the right ears of the mice 5 h 
before sensitization. Tlus resulted in sigilificant suppression of 
CHS: 67 .6% (p < 0.005) at 24 hand 72.4% (p < 0.005) at 48 h (Fig 
5). 
IL-1ra Does Not Suppress Phenol-Induced Inflammation 
To examine whether IL-lra has a suppressive effect on nonimmu-
nologic inflammation, we injected IL-lra into the ears 2 h before 
the treatment with 20% phenol. Phenol induced a moderate to 
severe increase in ear thickness at 3 to 6 h, which decreased at 12 
and 24 h in both IL-1ra-treated mice and PBS-treated control mice. 
The time course of the ear swelling for mice treated with IL- lra 
1 showed a pattern similar to that for mice treated with PBS, 
indicating no effect of IL-1 ra on phenol-induced inflammation 
' (Table I) . 
DISCUSSION 
In this report, we demonstrate that intradermal admitlistration of 
rhulL-lra (10-100 p.g/ear) suppressed the elicitation (Figs 1, 2) 
and the sensitization (Fig 5) phases of CHS in mice . The dose of 
IL-1ra showing suppressive effects in our i11 11il'o murine model is 
1 consistent with other previous iu rli11o studies [15,27,34). In the 
elicitation phase, the suppression was efficiently induced when 
IL-1ra was administered during the 12 h preceding topical applica-
tion of the contact sensitizer (Fig 3). By contrast, IL-lra adminis-
' tration even 1 h after DNFB painting was ineffective in causing 
significant CHS suppression (Fig 4). This latter observation con-
firms previous evidence that the dose and timing of cytokine 
1 
administration in 11i11o are critical in modulating CHS [27). One 
possible explanation for the lack of IL-1 ra effect when it is 
, administered after chalJenge is that keratinocytes, in response to 
contact with the hapten, express membrane-bound IL-l [35). Thus, 
IL-1 can illitiate a cascade of inflammatory and immunologic 
events, presumably too rapid to be blocked once tlus amplified 
cascade is initiated. 
We demonstrated that ear swelling was reduced approximately 
50% by IL-lra, but even with 100 p.g of IL-lra, no further 
reduction in CHS was aclueved (Fig 1). Tllis result suggests that 
although IL-l is necessary for optimal CHS induction, other 
mediators are likely to be involved in tlus elicitation process. In 
addition to the suppressive effects on the elicitation phase, IL-lra 
was revealed to have a potent inhibitory effect (approx-imately 70%) 
on the sensitization phase. 
By using IL-lra in the present study, we were able to block both 
IL-l a and IL-1 {3. Because IL-1ra has no agmlist activity when 
bound to IL-l receptors, our results suggest that IL-l, so abundant 
in the skin [36], is required for optimal CHS expression. IL-1 is one 
of many cytok:ines produced during CHS [37] . Although IL-1 has 
the potential to mediate events in the CHS response, its primary 
role in this disease process has not been established. Systemic 
administration ofrhuiL-1{3 to mice undergoing CHS demonstrated 
that this cytokine differentially affects the two phases (sensitization 
' and challenge) of the delayed-type immune reaction [27) . Thus, 
rbulL-1{3 exerted a net suppression of the final CHS response when 
it w as administered during the sensitization phase, but during the 
challenge phase, enhancement or suppression was found depending 
on the exact dose and time of admilustration [27]. Another group of 
investigators has shown that systemic administration of IL-l (puri-
fied from human callus stratum corneum) reduces murine CHS 
responses [28]. Our results showing sigi1.ificant differences in swell-
ing of hapten-challenged ears between the IL-lra-injected ears and 
the control PBS-injected contralateral ears (Fig 3) iiHiicate that 
local application of IL-lra blocked IL-l activiry without any 
systemic effect. Therefore, we conclude that the net effects of 
locally produced IL-l may exert a potent induction of the CHS 
reaction. 
Langcrhans cells are considered a principal target for IL-l activiry 
in the skin. It has been shown that IL-1 acts on cultured Langerhans 
cells, not only increasing tl1eir viability, but also enhancil1g their 
ability to activate allogeneic T cells when applied in conjunction 
with granulocyte macrophage-colony-stinmlating factor (38). Sev-
eral reports have suggested that sigilificant changes in IL-113 gene 
expression in Langerhans cells correlate with their functional 
activation as potent antigen-presenting cells both in 11itro and ir·r situ. 
IL-113 mRNA expression appeared to be up-regulated gradually but 
strongly during the 3-d Langerhans cell culture period, and this 
phenomenon has been considered specifically inherent to the 
maturation of cultured Langerhans cells i11to potent stimulatory 
dendritic cells (39). It is interesting that a similar change in IL-113 
gene expression was observed in Langerhans cells in situ after 
topical application of contact sensitizer [40). These authors also 
demonstrated that IL-la and IL-113 exerted different controls on 
CHS reactions and that only IL-1,8 plays a major role on the 
induction phase ofCHS [41) . Intradermal administration ofrecom-
bilmnt murine IL-113 caused cha11ges i11 the expression of cytokine 
mRNA in the epidermis very sinlilar to those resulting from topical 
application of allergens [41) . IL-113, but not IL-l a, was shown to 
up-regulate major lustocompatibility complex class II molecule 
expression on Langerhans cells i11 situ, again promoting the induc-
tion of CHS [ 41] . Moreover, intradermal it"Uection of anti-IL-113 
monoclonal antibody prevented effective sensitization to the sub-
sequent topical application of the contact sensitizer t:rit"Litrochloro-
benzene (41). On the other hand, a recent report has suggested that 
IL-l a may regulate the antigen-presenting function of Langerh311s 
cells .in the classic delayed-type hypersensitivity murine model [42). 
The suppressive effects of IL-lra on botl1 the sensitization and 
elicitation phases of CHS observed il1 the present study are 
supported by our previous observations that both phases of CHS 
show similar increases in IL-l a and IL-113 [ 43]. The suppressive 
effect on the sensitization phase (Fig 5, 67.6% to 72.4%) is sinular 
to the results of Enk et a/, [ 41] in which anti-IL-113 monoclonai 
a11tibody prevented sensitization. The lack of a suppressive effect of 
IL-lra on phenol-il1duced il1flammation is consistent with our 
previous results [ 43] showing that IL-113 mRNA is not up-regulated 
by 24 h after the itlitiation of irritant dem1atitis . The finding is also 
consistent with the results of Enk and Katz [40) , in which IL-113 
signals were up-regulated after allergen application but not after 
chemical irritants. These results suggest that IL-1 is not required for 
the induction of irritant dermatitis. 
Usi11g IL-1ra, we have demonstrated that IL-1 activity is required 
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for optimal development of CHS. Our murine data are consistent 
with a recent clinical trial showing that the human cutaneous 
allergic late-phase response was inhibited by soluble IL-1 receptor, 
which specifically inhibits IL-1 activity [44]. Our results showing 
IL- 1ra suppressive effects on CHS expression in mice emphasize the 
importance of IL-l as a potentiator of immune responses in the 
skin . 
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